Convalescent Plasma Collection and Treatment in Pediatrics and Adults

Description

This is a prospective study, involving contacting potential plasma donors and the use of their plasma to help fight off infections of those suffering from COVID19 in accordance to collection guidelines for plasma and FDA IND requirement. This study will include up to 240 participants potentially receiving convalescent plasma and up to 1000 potential donors. There are 3 basic arms to the study: mild, moderate and severe/critical severity. All 3 severity groups are eligible for enrollment, but mild severity will not be given plasma unless there is progression. Moderate severity will given up to 1 unit of plasma and severe/critical severity up to 2 units. There is no placebo group, however given the excepted issues of shortages of plasma, intention to treat will be used for analysis.

Conditions

COVID19, Coronavirus Infection, Coronavirus, Virus Diseases, RNA Virus Infections

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a prospective study, involving contacting potential plasma donors and the use of their plasma to help fight off infections of those suffering from COVID19 in accordance to collection guidelines for plasma and FDA IND requirement. This study will include up to 240 participants potentially receiving convalescent plasma and up to 1000 potential donors. There are 3 basic arms to the study: mild, moderate and severe/critical severity. All 3 severity groups are eligible for enrollment, but mild severity will not be given plasma unless there is progression. Moderate severity will given up to 1 unit of plasma and severe/critical severity up to 2 units. There is no placebo group, however given the excepted issues of shortages of plasma, intention to treat will be used for analysis.

Convalescent Plasma Collection From Individuals That Recovered From COVID19 and Treatment of Critically Ill Individuals With Donor Convalescent Plasma

Convalescent Plasma Collection and Treatment in Pediatrics and Adults

Condition
COVID19
Intervention / Treatment

-

Contacts and Locations

Morgantown

WVU Medicine, Morgantown, West Virginia, United States, 26506

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Plasma donation:
  • 1. Prior diagnosis of COVID-19 documented by a laboratory test
  • 1. Abbott RealTime SARS-CoV-2 real-time reverse transcription polymerase chain reaction (rRT-PCR) test on the Abbott m2000 System (Inpatient WVU testing)
  • 2. Other testing methods and vendors using FDA approved detection methods of SARS-CoV-2 under the Emergency Use Authorization (EUA)
  • 2. Complete resolution of symptoms at least 28 days prior to donation
  • 3. Complete resolution of symptoms for at least 14 days with negative repeat COVID-19 testing approved by the FDA EUA
  • 4. Female donors age 18+ that have never been pregnant or negative for HLA antibodies
  • 5. Male donors age 18+
  • 6. Negative results for COVID-19 either from one or more nasopharyngeal swab specimens or by a molecular diagnostic test from blood. A partial list of available tests can be accessed at https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations.
  • 7. Defined SARS-CoV-2 neutralizing antibody titers, if testing can be conducted (e.g., of at least 1:1602, 1:360 up to 1:640 is preferred. In shortage case 1:80 is acceptable)
  • 8. At least or greater than 50kg of weight
  • * Plasma Recipients:
  • 1. Individuals of any age above 30 days of life, sex, or pregnancy status suffering from confirmed COVID19 and in rapid progression, severe or critical condition meeting the FDA IND guidelines.
  • 2. Must have laboratory confirmed COVID19
  • 3. Must have severe or immediately life-threatening COVID19
  • 4. Must provide informed consent/assent
  • * Plasma donation:
  • 1. Individuals that do not meet the requirement from the American Red Cross for plasma donation or equivalent
  • 2. Individuals plasma that has not passed safety screening after procurement by the American Red Cross for plasma donation or equivalent
  • * Plasma Recipients
  • 1. Individuals with COVID19 who are not in clinical concern for rapid progression, severe or critical condition
  • 2. Individuals who are in critical condition that are not confirmed to have COVID19
  • 3. Individuals with known Selective IgA Deficiency, that has not been found to be absent of anti-IgA antibodies

Ages Eligible for Study

31 Days to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

West Virginia University,

Brian Peppers, DO, PhD, PRINCIPAL_INVESTIGATOR, WVU Medicine Children's

Study Record Dates

2021-03-30